

Table 4.25

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	312,306	99.4%	246,298	99.5%	34,895	99.3%	26,564	99.3%	1,339	99.3%	34,553	99.2%
Epidermoid carcinoma ^d (8051-8131)	168	0.1%	135	0.1%	21	0.1%	-	-	-	-	18	0.1%
Adenocarcinoma ^e	306,400	97.6%	241,894	97.7%	33,862	96.4%	26,188	97.9%	1,313	97.4%	33,827	97.1%
Adenocarcinoma, NOS (8140)	2,153	0.7%	1,672	0.7%	288	0.8%	147	0.5%	-	-	237	0.7%
Infiltrating duct carcinoma (8500)	230,651	73.4%	179,993	72.7%	26,415	75.2%	20,848	77.9%	1,032	76.6%	25,986	74.6%
Lobular carcinoma, NOS (8520)	29,780	9.5%	25,105	10.1%	2,657	7.6%	1,618	6.0%	106	7.9%	2,710	7.8%
Inflammatory adenocarcinoma (8530)	826	0.3%	646	0.3%	117	0.3%	53	0.2%	-	-	143	0.4%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	28,414	9.0%	23,261	9.4%	2,617	7.4%	2,144	8.0%	101	7.5%	3,288	9.4%
Mucinous adenocarcinoma (8480,8482)	6,000	1.9%	4,513	1.8%	755	2.1%	656	2.5%	20	1.5%	611	1.8%
Mucin-producing adenocarcinoma (8481)	59	0.0%	45	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	1,627	0.5%	1,439	0.6%	104	0.3%	65	0.2%	-	-	118	0.3%
Papillary adenocarcinoma (8050,8260,8503,8504)	2,037	0.6%	1,438	0.6%	317	0.9%	237	0.9%	-	-	226	0.6%
Paget disease (8540-8543)	1,085	0.3%	854	0.3%	124	0.4%	94	0.4%	-	-	111	0.3%
Other adenocarcinomas ^f	3,768	1.2%	2,928	1.2%	458	1.3%	324	1.2%	-	-	391	1.1%
Other specific carcinomas ^g	2,502	0.8%	1,838	0.7%	459	1.3%	180	0.7%	-	-	322	0.9%
Medullary adenocarcinoma (8510-8513)	661	0.2%	446	0.2%	164	0.5%	43	0.2%	-	-	135	0.4%
Other ^h	1,841	0.6%	1,392	0.6%	295	0.8%	137	0.5%	-	-	187	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,236	1.0%	2,431	1.0%	553	1.6%	185	0.7%	-	-	386	1.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	323	0.1%	245	0.1%	52	0.1%	22	0.1%	-	-	43	0.1%
Hemangiosarcomas (9120-9126,9170)	166	0.1%	140	0.1%	17	0.0%	-	-	-	-	19	0.1%
Other sarcomas ^d	157	0.1%	105	0.0%	35	0.1%	-	-	-	-	24	0.1%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	723	0.2%	499	0.2%	90	0.3%	115	0.4%	-	-	142	0.4%
Phyllodes tumor, malignant (9020)	612	0.2%	420	0.2%	68	0.2%	105	0.4%	-	-	126	0.4%
Other ^e	111	0.0%	79	0.0%	22	0.1%	-	-	-	-	16	0.0%
Unspecified (8000-8005)	699	0.2%	526	0.2%	102	0.3%	46	0.2%	-	-	97	0.3%
Total ^f	314,051	100.0%	247,568	100.0%	35,139	100.0%	26,747	100.0%	1,348	100.0%	34,835	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	77,883	99.9%	58,870	99.9%	9,149	99.9%	8,401	99.9%	306	100.0%	8,297	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	66,284	85.0%	49,479	84.0%	8,046	87.9%	7,615	90.6%	270	88.2%	7,115	85.6%
Cribriform carcinoma <i>in situ</i> (8201/2)	7,009	9.0%	5,171	8.8%	863	9.4%	861	10.2%	18	5.9%	742	8.9%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,636	7.2%	4,353	7.4%	577	6.3%	615	7.3%	27	8.8%	508	6.1%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	20,775	26.6%	15,828	26.9%	2,441	26.7%	2,074	24.7%	104	34.0%	2,209	26.6%
Comedocarcinoma <i>in situ</i> (8501/2)	6,493	8.3%	4,846	8.2%	745	8.1%	798	9.5%	33	10.8%	678	8.2%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,132	1.5%	762	1.3%	208	2.3%	139	1.7%	-	-	122	1.5%
Noninfiltrating intracystic carcinoma(8504/2)	255	0.3%	162	0.3%	42	0.5%	49	0.6%	-	-	28	0.3%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,210	1.6%	926	1.6%	162	1.8%	102	1.2%	-	-	138	1.7%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	23,587	30.3%	17,299	29.4%	2,997	32.7%	2,934	34.9%	82	26.8%	2,673	32.2%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	9,076	11.6%	7,418	12.6%	812	8.9%	560	6.7%	32	10.5%	933	11.2%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	9,063	11.6%	7,410	12.6%	808	8.8%	560	6.7%	31	10.1%	932	11.2%
Lobular CIS ^f with other CIS ^f (8524/2)	-	-	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,016	2.6%	1,602	2.7%	228	2.5%	162	1.9%	-	-	195	2.3%
Other adenocarcinomas ^g	499	0.6%	367	0.6%	62	0.7%	61	0.7%	-	-	54	0.7%
Other <i>in situ</i> histologies ^h	77	0.1%	59	0.1%	-	-	-	-	-	-	-	-
Total	77,960	100.0%	58,929	100.0%	9,155	100.0%	8,407	100.0%	306	100.0%	8,308	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,209	97.9%	12,057	98.1%	2,214	96.7%	1,555	98.6%	134	97.8%	3,579	98.0%
Epidermoid carcinoma ^d (8050-8131)	10,744	64.9%	7,762	63.1%	1,691	73.9%	1,021	64.7%	96	70.1%	2,434	66.6%
Squamous cell carcinoma (8070)	7,581	45.8%	5,447	44.3%	1,222	53.4%	719	45.6%	79	57.7%	1,632	44.7%
Squamous cell, keratinizing (8071)	1,110	6.7%	780	6.3%	207	9.0%	99	6.3%	-	-	269	7.4%
Squamous cell, non-keratinizing (8072)	1,434	8.7%	1,083	8.8%	175	7.6%	147	9.3%	-	-	389	10.7%
Squamous cell, Microinvasive (8076)	346	2.1%	261	2.1%	40	1.7%	27	1.7%	-	-	76	2.1%
Other (8050-8069, 8073-8075,8077-8131)	273	1.6%	191	1.6%	47	2.1%	29	1.8%	-	-	68	1.9%
Adenocarcinoma ^e	4,748	28.7%	3,784	30.8%	407	17.8%	460	29.2%	34	24.8%	1,003	27.5%
Adenocarcinoma, NOS (8140)	2,461	14.9%	1,964	16.0%	212	9.3%	231	14.6%	-	-	528	14.5%
Adenosquamous (8560,8570)	542	3.3%	401	3.3%	62	2.7%	72	4.6%	-	-	140	3.8%
Other adenocarcinomas ^f	1,745	10.5%	1,419	11.5%	133	5.8%	157	10.0%	-	-	335	9.2%
Other specific carcinomas ^g	302	1.8%	212	1.7%	49	2.1%	36	2.3%	-	-	55	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	415	2.5%	299	2.4%	67	2.9%	38	2.4%	-	-	87	2.4%
Sarcoma ^h	64	0.4%	42	0.3%	17	0.7%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	172	1.0%	112	0.9%	35	1.5%	17	1.1%	-	-	29	0.8%
Unspecified (8000-8005)	115	0.7%	83	0.7%	23	1.0%	-	-	-	-	29	0.8%
Total	16,560	100.0%	12,294	100.0%	2,289	100.0%	1,577	100.0%	137	100.0%	3,652	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	179,444	99.5%	139,111	99.5%	22,002	99.5%	15,055	99.4%	1,114	99.3%	20,395	99.4%
Epidermoid carcinoma ^d (8051-8131)	1,212	0.7%	1,036	0.7%	124	0.6%	23	0.2%	-	-	101	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	1,173	0.7%	1,007	0.7%	120	0.5%	22	0.1%	-	-	97	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	166,146	92.1%	129,982	93.0%	19,713	89.1%	13,858	91.5%	1,024	91.3%	18,742	91.3%
Adenocarcinoma, NOS (8140)	114,035	63.2%	89,047	63.7%	13,451	60.8%	9,989	65.9%	735	65.5%	13,013	63.4%
Adenocarcinoma in adenomatous polyp (8210)	15,834	8.8%	12,226	8.7%	1,882	8.5%	1,304	8.6%	119	10.6%	1,432	7.0%
Adenocarcinoma in villous adenoma (8261)	3,394	1.9%	2,713	1.9%	392	1.8%	247	1.6%	-	-	464	2.3%
Mucinous adenocarcinoma (8470-8473,8480,8482)	11,319	6.3%	9,293	6.6%	1,160	5.2%	746	4.9%	54	4.8%	1,439	7.0%
Mucin-producing adenocarcinoma (8481)	1,183	0.7%	910	0.7%	176	0.8%	87	0.6%	-	-	137	0.7%
Signet ring adenocarcinoma (8490)	2,052	1.1%	1,670	1.2%	224	1.0%	138	0.9%	-	-	249	1.2%
Other adenocarcinomas ^e	18,329	10.2%	14,123	10.1%	2,428	11.0%	1,347	8.9%	93	8.3%	2,008	9.8%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	10,702	5.9%	7,023	5.0%	1,990	9.0%	1,074	7.1%	67	6.0%	1,388	6.8%
Neuroendocrine carcinoid (8240-8245)	7,941	4.4%	4,992	3.6%	1,568	7.1%	855	5.6%	59	5.3%	1,100	5.4%
Other ^f	2,761	1.5%	2,031	1.5%	422	1.9%	219	1.4%	-	-	288	1.4%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,384	0.8%	1,070	0.8%	175	0.8%	100	0.7%	18	1.6%	164	0.8%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	115	0.1%	89	0.1%	16	0.1%	-	-	-	-	17	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	285	0.2%	195	0.1%	41	0.2%	46	0.3%	-	-	39	0.2%
Unspecified (8000-8005)	542	0.3%	427	0.3%	58	0.3%	44	0.3%	-	-	75	0.4%
Total ^d	180,386	100.0%	139,822	100.0%	22,117	100.0%	15,153	100.0%	1,122	100.0%	20,526	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	19,194	99.2%	16,245	99.2%	1,883	99.4%	866	99.1%	82	98.8%	1,505	98.8%
Epidermoid carcinoma ^d (8051-8131)	6,139	31.7%	4,003	24.4%	1,479	78.0%	594	68.0%	33	39.8%	522	34.3%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,121	31.6%	3,995	24.4%	1,471	77.6%	593	67.8%	33	39.8%	522	34.3%
Adenocarcinoma ^e	12,282	63.5%	11,577	70.7%	338	17.8%	240	27.5%	47	56.6%	916	60.1%
Other specific carcinomas ^f	289	1.5%	244	1.5%	24	1.3%	19	2.2%	-	-	22	1.4%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	484	2.5%	421	2.6%	42	2.2%	-	-	-	-	45	3.0%
Other specific types ^g	63	0.3%	51	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	90	0.5%	79	0.5%	-	-	-	-	-	-	-	-
Total	19,347	100.0%	16,375	100.0%	1,895	100.0%	874	100.0%	83	100.0%	1,524	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other specific types includes sarcomas and other soft tissue tumors.

ⁱ Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	24,231	97.2%	17,307	97.2%	3,146	97.3%	3,378	97.4%	221	95.7%	4,245	96.2%
Hepatocellular carcinoma ^d (8170-8175)	17,820	71.5%	12,264	68.9%	2,556	79.1%	2,661	76.7%	180	77.9%	3,265	74.0%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	5,466	21.9%	4,363	24.5%	450	13.9%	603	17.4%	34	14.7%	822	18.6%
Other carcinoma ^e	943	3.8%	679	3.8%	140	4.3%	113	3.3%	-	-	158	3.6%
Other specific carcinoma ^f	608	2.4%	434	2.4%	84	2.6%	82	2.4%	-	-	97	2.2%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	335	1.3%	245	1.4%	56	1.7%	31	0.9%	-	-	61	1.4%
Hepatoblastoma (8970)	248	1.0%	181	1.0%	30	0.9%	29	0.8%	-	-	78	1.8%
Sarcoma ^g	220	0.9%	158	0.9%	20	0.6%	39	1.1%	-	-	35	0.8%
Hemangiosarcoma (9120)	106	0.4%	74	0.4%	-	-	23	0.7%	-	-	-	-
Other sarcomas ^h	114	0.5%	84	0.5%	-	-	16	0.5%	-	-	20	0.5%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	44	0.2%	32	0.2%	-	-	-	-	-	-	16	0.4%
Unspecified (8000-8004)	176	0.7%	125	0.7%	27	0.8%	19	0.5%	-	-	37	0.8%
Total ^d	24,924	100.0%	17,806	100.0%	3,232	100.0%	3,469	100.0%	231	100.0%	4,412	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^e Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^f Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

^h Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	48.1	227,250	99.7%	184,947	99.7%	25,930	99.8%	14,663	99.8%	825	99.5%	13,448	99.5%
Small cell (8002,8041-8045)	6.1	29,501	12.9%	25,602	13.8%	2,650	10.2%	1,047	7.1%	119	14.4%	1,416	10.5%
Non-small cell	40.6	191,281	83.9%	154,148	83.1%	22,467	86.4%	13,215	89.9%	676	81.5%	11,578	85.6%
Squamous and transitional cell ^d	11.4	52,928	23.2%	43,862	23.6%	6,370	24.5%	2,265	15.4%	246	29.7%	2,579	19.1%
Adenocarcinoma ^e	23.1	109,146	47.9%	86,323	46.5%	12,597	48.5%	9,447	64.3%	322	38.8%	7,038	52.1%
Large cell ^f	0.7	3,407	1.5%	2,781	1.5%	453	1.7%	155	1.1%	-	-	166	1.2%
Non-small cell carcinoma ^g	2.9	13,900	6.1%	11,060	6.0%	1,915	7.4%	798	5.4%	65	7.8%	889	6.6%
Other specified carcinomas ^h	2.5	11,900	5.2%	10,122	5.5%	1,132	4.4%	550	3.7%	36	4.3%	906	6.7%
Carcinoma, NOS ⁱ	1.4	6,468	2.8%	5,197	2.8%	813	3.1%	401	2.7%	30	3.6%	454	3.4%
Sarcoma ^j	0.1	419	0.2%	350	0.2%	41	0.2%	20	0.1%	-	-	53	0.4%
Other specified types ^k	0.0	220	0.1%	184	0.1%	24	0.1%	-	-	-	-	17	0.1%
Total	48.3	227,889	100.0%	185,481	100.0%	25,995	100.0%	14,694	100.0%	829	100.0%	13,518	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Males by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	55.9	118,319	99.7%	95,050	99.7%	14,277	99.7%	8,116	99.8%	429	99.5%	7,041	99.4%
Small cell (8002,8041-8045)	6.7	14,553	12.3%	12,399	13.0%	1,349	9.4%	698	8.6%	63	14.6%	734	10.4%
Non-small cell	47.4	100,099	84.3%	79,766	83.6%	12,422	86.8%	7,174	88.2%	348	80.7%	6,036	85.2%
Squamous and transitional cell ^d	15.8	32,875	27.7%	26,988	28.3%	4,001	27.9%	1,625	20.0%	142	32.9%	1,633	23.1%
Adenocarcinoma ^e	24.5	52,016	43.8%	40,576	42.5%	6,467	45.2%	4,627	56.9%	142	32.9%	3,384	47.8%
Large cell ^f	0.9	1,930	1.6%	1,543	1.6%	275	1.9%	100	1.2%	-	-	102	1.4%
Non-small cell carcinoma ^g	3.7	7,904	6.7%	6,175	6.5%	1,133	7.9%	529	6.5%	39	9.0%	509	7.2%
Other specified carcinomas ^h	2.5	5,374	4.5%	4,484	4.7%	546	3.8%	293	3.6%	21	4.9%	408	5.8%
Carcinoma, NOS ⁱ	1.8	3,667	3.1%	2,885	3.0%	506	3.5%	244	3.0%	18	4.2%	271	3.8%
Sarcoma ^j	0.1	252	0.2%	214	0.2%	22	0.2%	-	-	-	-	33	0.5%
Other specified types ^k	0.1	131	0.1%	107	0.1%	16	0.1%	-	-	-	-	-	-
Total	56.1	118,702	100.0%	95,371	100.0%	14,315	100.0%	8,135	100.0%	431	100.0%	7,081	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	42.2	108,931	99.8%	89,897	99.8%	11,653	99.8%	6,547	99.8%	396	99.5%	6,407	99.5%
Small cell (8002,8041-8045)	5.7	14,948	13.7%	13,203	14.7%	1,301	11.1%	349	5.3%	56	14.1%	682	10.6%
Non-small cell	35.4	91,182	83.5%	74,382	82.5%	10,045	86.0%	6,041	92.1%	328	82.4%	5,542	86.1%
Squamous and transitional cell ^d	7.9	20,053	18.4%	16,874	18.7%	2,369	20.3%	640	9.8%	104	26.1%	946	14.7%
Adenocarcinoma ^e	22.1	57,130	52.3%	45,747	50.8%	6,130	52.5%	4,820	73.5%	180	45.2%	3,654	56.8%
Large cell ^f	0.6	1,477	1.4%	1,238	1.4%	178	1.5%	55	0.8%	-	-	64	1.0%
Non-small cell carcinoma ^g	2.3	5,996	5.5%	4,885	5.4%	782	6.7%	269	4.1%	26	6.5%	380	5.9%
Other specified carcinomas ^h	2.5	6,526	6.0%	5,638	6.3%	586	5.0%	257	3.9%	-	-	498	7.7%
Carcinoma, NOS ⁱ	1.1	2,801	2.6%	2,312	2.6%	307	2.6%	157	2.4%	-	-	183	2.8%
Sarcoma ^j	0.1	167	0.2%	136	0.2%	19	0.2%	-	-	-	-	20	0.3%
Other specified types ^k	0.0	89	0.1%	77	0.1%	-	-	-	-	-	-	-	-
Total	42.3	109,187	100.0%	90,110	100.0%	11,680	100.0%	6,559	100.0%	398	100.0%	6,437	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	46,146	85.3%	3,036	94.6%	16,242	97.5%	1,326	22.4%	2,311	95.2%
Squamous cell carcinoma (8070-8078,8083-8084)	45,094	83.4%	2,892	90.1%	15,980	96.0%	1,269	21.4%	2,285	94.1%
Adenocarcinoma ^c	5,232	9.7%	126	3.9%	208	1.2%	3,665	61.8%	88	3.6%
Other specific carcinomas ^d	487	0.9%	-	-	43	0.3%	290	4.9%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,536	2.8%	-	-	84	0.5%	426	7.2%	-	-
Sarcoma and soft tissue ^e	177	0.3%	-	-	22	0.1%	37	0.6%	-	-
Other specific types ^f	299	0.6%	25	0.8%	-	-	128	2.2%	-	-
Unspecified (8000-8005)	201	0.4%	-	-	41	0.2%	56	0.9%	-	-
Total	54,079	100.0%	3,210	100.0%	16,653	100.0%	5,928	100.0%	2,428	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,845	82.8%	1,809	64.7%	11,912	98.2%	2,691	97.1%	974	88.9%
Squamous cell carcinoma (8070-8078,8083-8084)	5,569	78.9%	1,678	60.0%	11,781	97.1%	2,677	96.6%	963	87.9%
Adenocarcinoma ^c	971	13.8%	80	2.9%	61	0.5%	-	-	20	1.8%
Other specific carcinomas ^d	35	0.5%	36	1.3%	37	0.3%	22	0.8%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	57	0.8%	807	28.8%	82	0.7%	22	0.8%	41	3.7%
Sarcoma and soft tissue ^e	34	0.5%	36	1.3%	-	-	-	-	-	-
Other specific types ^f	100	1.4%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	17	0.2%	-	-	24	0.2%	-	-	36	3.3%
Total	7,060	100.0%	2,798	100.0%	12,136	100.0%	2,770	100.0%	1,096	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,896	91.3%	20,294	92.0%	2,093	86.9%	2,218	91.4%	116	84.7%	3,229	87.4%
Epidermoid carcinoma ^d (8051-8131)	157	0.6%	118	0.5%	16	0.7%	23	0.9%	-	-	29	0.8%
Adenocarcinoma ^e	22,978	84.3%	18,850	85.4%	1,824	75.7%	2,043	84.2%	110	80.3%	2,930	79.3%
Adenocarcinoma, NOS (8140)	2,814	10.3%	2,284	10.3%	334	13.9%	167	6.9%	-	-	361	9.8%
Papillary adenocarcinoma, NOS (8050,8260)	241	0.9%	189	0.9%	33	1.4%	17	0.7%	-	-	28	0.8%
Clear cell adenocarcinoma (8310,9110)	1,526	5.6%	1,134	5.1%	79	3.3%	296	12.2%	-	-	182	4.9%
Endometrioid carcinoma (8380-8383,8570)	2,652	9.7%	2,158	9.8%	143	5.9%	317	13.1%	-	-	405	11.0%
Cystadenocarcinoma, NOS (8440,8450)	48	0.2%	41	0.2%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	8,574	31.5%	7,150	32.4%	672	27.9%	647	26.7%	49	35.8%	960	26.0%
Papillary serous cystadenocarcinoma (8460-8462)	4,216	15.5%	3,534	16.0%	358	14.9%	283	11.7%	18	13.1%	566	15.3%
Mucinous cystadenocarcinoma (8470-8473)	312	1.1%	241	1.1%	22	0.9%	44	1.8%	-	-	47	1.3%
Mucinous adenocarcinoma (8480,8482)	1,142	4.2%	913	4.1%	85	3.5%	128	5.3%	-	-	150	4.1%
Mucin-producing adenocarcinoma(8481)	22	0.1%	-	-	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,431	5.3%	1,192	5.4%	90	3.7%	137	5.6%	-	-	221	6.0%
Other specific carcinomas ^g	665	2.4%	452	2.0%	141	5.9%	56	2.3%	-	-	117	3.2%
Stromal cell tumor (8620-8631,8650)	488	1.8%	316	1.4%	120	5.0%	39	1.6%	-	-	89	2.4%
Other ^h	177	0.6%	136	0.6%	21	0.9%	17	0.7%	-	-	28	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,096	4.0%	874	4.0%	112	4.7%	96	4.0%	-	-	153	4.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	81	0.3%	59	0.3%	18	0.7%	-	-	-	-	19	0.5%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,973	7.2%	1,496	6.8%	247	10.3%	181	7.5%	16	11.7%	399	10.8%
Mullerian mixed tumor (8950-8951,8980)	936	3.4%	765	3.5%	95	3.9%	59	2.4%	-	-	112	3.0%
Teratoma, malignant (9080-9085,9102)	410	1.5%	263	1.2%	74	3.1%	54	2.2%	-	-	133	3.6%
Other	627	2.3%	468	2.1%	78	3.2%	68	2.8%	-	-	154	4.2%
Unspecified (8000-8005)	305	1.1%	220	1.0%	50	2.1%	26	1.1%	-	-	49	1.3%
Total ^d	27,255	100.0%	22,069	100.0%	2,408	100.0%	2,427	100.0%	137	100.0%	3,696	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	48,641	98.3%	38,647	98.3%	5,920	98.4%	3,656	98.1%	194	96.5%	5,268	97.9%
Epidermoid carcinoma ^d (8051-8131)	145	0.3%	105	0.3%	22	0.4%	16	0.4%	-	-	-	-
Adenocarcinoma ^e	42,038	84.9%	33,498	85.2%	5,105	84.8%	3,092	83.0%	171	85.1%	4,532	84.2%
Adenocarcinoma, NOS (8140)	33,949	68.6%	27,067	68.8%	4,218	70.1%	2,388	64.1%	142	70.6%	3,603	67.0%
Papillary adenocarcinoma, NOS (8260)	30	0.1%	25	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,114	2.3%	885	2.3%	103	1.7%	111	3.0%	-	-	136	2.5%
Mucin-producing adenocarcinoma (8481)	296	0.6%	238	0.6%	36	0.6%	21	0.6%	-	-	27	0.5%
Infiltrating duct carcinoma (8500-8503,8507,8514)	5,282	10.7%	4,192	10.7%	589	9.8%	468	12.6%	17	8.5%	564	10.5%
Other adenocarcinoma ^f	1,367	2.8%	1,091	2.8%	157	2.6%	101	2.7%	-	-	196	3.6%
Other specific carcinomas ^g	4,641	9.4%	3,651	9.3%	540	9.0%	391	10.5%	16	8.0%	508	9.4%
Islet cell carcinoma (8150-8155)	275	0.6%	228	0.6%	27	0.4%	16	0.4%	-	-	25	0.5%
Other carcinomas ^h	4,366	8.8%	3,423	8.7%	513	8.5%	375	10.1%	-	-	483	9.0%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	1,818	3.7%	1,394	3.5%	253	4.2%	157	4.2%	-	-	216	4.0%
Sarcoma and other soft tissue tumors ⁱ	40	0.1%	32	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	53	0.1%	42	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	764	1.5%	602	1.5%	90	1.5%	63	1.7%	-	-	94	1.7%
Total	49,499	100.0%	39,324	100.0%	6,019	100.0%	3,727	100.0%	201	100.0%	5,381	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	30,245	91.9%	21,561	92.7%	3,921	87.0%	4,222	92.6%	250	96.2%	5,790	94.7%
Epidermoid carcinoma ^d (8051-8131)	285	0.9%	193	0.8%	60	1.3%	28	0.6%	-	-	27	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	276	0.8%	185	0.8%	60	1.3%	27	0.6%	-	-	25	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	26,838	81.5%	19,017	81.7%	3,423	75.9%	3,970	87.1%	222	85.4%	5,112	83.7%
Adenocarcinoma, NOS (8140)	15,507	47.1%	11,441	49.2%	1,925	42.7%	1,909	41.9%	127	48.8%	2,436	39.9%
Adenocarcinoma, intestinal type (8144)	2,758	8.4%	1,620	7.0%	440	9.8%	658	14.4%	24	9.2%	552	9.0%
Carcinoma, diffuse type (8145)	1,312	4.0%	820	3.5%	144	3.2%	320	7.0%	-	-	360	5.9%
Linitus plastica (8142)	167	0.5%	125	0.5%	-	-	27	0.6%	-	-	39	0.6%
Mucinous adenocarcinoma (8470-8473,8480,8482)	381	1.2%	268	1.2%	55	1.2%	50	1.1%	-	-	63	1.0%
Mucin-producing adenocarcinoma (8481)	97	0.3%	73	0.3%	16	0.4%	-	-	-	-	17	0.3%
Signet ring adenocarcinoma (8490)	5,375	16.3%	3,801	16.3%	657	14.6%	817	17.9%	51	19.6%	1,392	22.8%
Other adenocarcinomas ^e	1,241	3.8%	869	3.7%	173	3.8%	181	4.0%	-	-	253	4.1%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	2,482	7.5%	1,909	8.2%	335	7.4%	138	3.0%	22	8.5%	533	8.7%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	640	1.9%	442	1.9%	103	2.3%	86	1.9%	-	-	118	1.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	87	0.3%	73	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	2,424	7.4%	1,520	6.5%	560	12.4%	310	6.8%	-	-	265	4.3%
Unspecified (8000-8005)	161	0.5%	112	0.5%	19	0.4%	24	0.5%	-	-	47	0.8%
Total ^d	32,917	100.0%	23,266	100.0%	4,509	100.0%	4,560	100.0%	260	100.0%	6,111	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	65,324	99.7%	52,285	99.7%	4,627	99.7%	6,858	99.7%	314	100.0%	10,507	99.7%
Epidermoid carcinoma ^d (8051-8131)	69	0.1%	56	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	63,330	96.6%	50,684	96.7%	4,448	95.8%	6,675	97.0%	305	97.1%	10,208	96.9%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	58,812	89.8%	47,185	90.0%	3,912	84.3%	6,286	91.4%	283	90.1%	9,606	91.2%
Follicular carcinoma (8330-8332,8335)	2,966	4.5%	2,258	4.3%	382	8.2%	268	3.9%	-	-	424	4.0%
Oxyphilic (8290)	1,205	1.8%	968	1.8%	120	2.6%	86	1.3%	-	-	139	1.3%
Other specific carcinomas ^f	1,100	1.7%	921	1.8%	84	1.8%	78	1.1%	-	-	172	1.6%
Medullary carcinoma (8510)	1,057	1.6%	886	1.7%	81	1.7%	74	1.1%	-	-	165	1.6%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	825	1.3%	624	1.2%	91	2.0%	97	1.4%	-	-	120	1.1%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	524	0.8%	408	0.8%	49	1.1%	62	0.9%	-	-	78	0.7%
Sarcoma and other soft tissue tumors ^g	17	0.0%	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	180	0.3%	130	0.2%	-	-	20	0.3%	-	-	23	0.2%
Total	65,528	100.0%	52,436	100.0%	4,642	100.0%	6,878	100.0%	314	100.0%	10,536	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^g Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^h Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.